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Abstract
First isolated in the early 1960s, doxorubicin (DOX) is among the most effective antican-
cer agents ever developed. DOX has been used mainly for the treatment of breast cancer, 
solid tumors in children, soft tissue sarcomas, and aggressive lymphomas. However, the 
use of DOX may have dose-dependent cardiotoxic effects that generate changes in myo-
cardial structure, which can develop into severe and irreversible cardiomyopathy. Here, 
we describe the incidence of DOX-induced cardiotoxicity (DIC); the progress made over 
the past four decades in understanding the molecular mechanisms of the pathogenesis of 
acute and chronic DIC; the current strategies for heart protection; and the major break-
throughs and challenges in basic and clinical research to the development of efficient 
targeted therapy for DIC.
Keywords: doxorubicin, chemotherapy, cardiotoxicity, mechanisms, pathogenesis, 
heart protection, targeted therapy
1. Introduction
Cardiomyopathy induced by doxorubicin (DOX) is considered an extremely serious adverse 
effect of oncologic treatment. It is known that this disease significantly affects the quality of 
patients’ life who survived cancer, especially children. Since its discovery, several molecular 
mechanisms have been proposed to understand the pathogenesis of acute and chronic DOX-
induced cardiotoxicity (DIC), including oxidative stress, iron metabolism, Ca2+ homeostasis 
dysregulation, sarcomeric structure alterations, gene expression modulation, and apoptosis. 
Based on these mechanisms, different strategies have been developed in order to protect the 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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heart during cancer treatment, including the administration of iron-chelating antioxidants 
and adrenergic receptor agonists. However, the use of these drugs is limited due to their 
adverse side effects as well as the loss of beneficial cardiac effects years after the end of the 
treatment. Therefore, the development of new therapies has been a great challenge for the 
scientific community. In this context, a new emergent strategy is cell therapy. Considering 
that DOX causes cardiomyocyte death, the transplant of autologous cardiomyocytes obtained 
through the differentiation of human induced pluripotent stem cells (iPSC) is a viable option 
for cardiac repair and a promising therapeutic strategy for the treatment of cardiovascular 
diseases, including DIC.
2. Doxorubicin
DOX (also known as adriamycin) was isolated in the early 1960s from the pigment-producing 
bacterium Streptomyces peucetius var. caesius, along with daunorubicin (DAU, also known as 
daunomycin and rubidomycin), and belongs to the family of anthracyclines [1–3]. Until to 
now, DOX remains among the most largely prescribed and effective antineoplastic agents 
ever developed for the treatment of a variety of adult and pediatric cancers [3–5]. Whereas 
DAU has been used against acute lymphoblastic and myeloblastic leukemias, DOX has been 
used against breast cancer, soft tissue sarcomas, childhood tumors (e.g., Wilms’ tumor), leu-
kemias, Hodgkin’s and non-Hodgkin’s lymphoma, and many other cancers [4, 5].
The minor differences in the chemical structure between DOX and DAU are responsible for 
the different spectrums of activity of these drugs. The side chain of DOX terminates with 
primary alcohol, while that of DAU terminates with a methyl group [3, 6]. Unfortunately, 
in addition to its potent antitumor effect, the use of DOX has been hampered by conven-
tional toxicities (hematopoietic suppression, nausea, vomiting, extravasation, and alope-
cia), development of resistant tumor cells or toxicity in healthy tissues, especially with 
serious cardiac toxicity manifested by congestive cardiomyopathy [4, 7]. Over time, more 
than 2000 analogs were developed in an attempt to reduce the adverse effects of DOX and 
DAU. However, few analogs have reached the stage of clinical development and approval, 
such as epirubicin (EPI) and idarubicin (IDA), with DOX- and DAU-like spectrums, respec-
tively [6]. Despite the development of new components, replacing DOX does not eliminate 
the risk of developing cardiotoxicity [6, 7]. Thus, DOX continues to be considered as a first-
line antineoplastic drug [7].
2.1. DOX-induced cardiotoxicity: clinical aspects
Since the late 1970s, DOX-induced cardiotoxicity (DIC) has been recognized as a complication 
of chemotherapy [5]. The first case report in the literature was that of a 23-year-old patient 
with osteosarcoma, who was treated for 9 months with DOX. One month after the end of 
treatment, the patient died due to development of congestive heart failure [8]. A second report 
describes the case of an 11-year-old patient, also with osteosarcoma, who died 9.5 years after 
the end of chemotherapy with DOX as a result of progressive heart failure with late severity 
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[9]. In 1991, long-term cardiotoxic effects were identified in patients with acute lymphoid 
leukemia in childhood [10]. Patients with childhood cancer and those treated with DOX have 
a high risk of developing symptomatic cardiac events at an early stage, and this risk remains 
high within 30 years after treatment. In addition, it is estimated that one in eight DOX-treated 
patients will be afflicted with severe cardiac disease [11].
DIC manifests in several forms, ranging from asymptomatic electrocardiography (ECG)-
changes to decompensated cardiomyopathy characterized by decreased left ventricular ejec-
tion fraction [4, 7]. According to their clinical manifestation, these cardiotoxic events can 
be classified into three types: (1) acute, occurring during or immediately after treatment; 
(2) early-onset chronic progressive cardiotoxicity, occurring within 1 year after exposure to 
chemotherapeutic treatment; and (3) late-onset chronic progressive cardiotoxicity, occurring 
1 or more years after the end of treatment [11].
Acute cardiotoxicity is characterized by depression of myocardial contractility that may be 
reversible within 1 week when discontinuing the DOX treatment [12, 13]. In some patients, 
complications have already been described, such as hypotension; pericarditis; myocarditis; 
supraventricular, ventricular, or sinus (more common) tachycardia; ST-T wave changes; 
decrease in QRS complex; prolongation of QT interval; and increase in serum levels of brain 
natriuretic peptide and cardiac troponin [3, 12–14]. However, this type of cardiotoxicity is 
very rare and affects less than 1% of patients [12].
Early-onset chronic progressive cardiotoxicity is characterized by systolic or diastolic ventric-
ular dysfunction within 1 year after the completion of DOX treatment. It can be progressive 
and occurs in 5–35% of the cases [11, 14, 15]. In the majority of adult patients, early cardiotox-
icity is related to the development of a chronic dilated cardiomyopathy, with a decrease in 
the mass and wall of left ventricle. In the pediatric patient, in addition to chronic dilated car-
diomyopathy, restrictive cardiomyopathy characterized by increase in the wall stiffness of the 
left ventricle cavity may also occur in isolated moments [11–13]. The typical manifestation of 
these cardiomyopathies is the progressive reduction of the ejection fraction [13]. Other events, 
including severe electrical conduction changes, damage to cardiac valves, and/or depression 
of contractility may also be observed [15].
Finally, late-onset chronic progressive cardiotoxicity is characterized by cardiac dysfunc-
tion after a latency period of 1 or more years following the completion of DOX treatment 
[12, 13]. In this type of cardiotoxicity, there is a period during which the patient is asymp-
tomatic (normal cardiac function). After that, chronic dilated and/or restrictive cardiomy-
opathy can be manifested with subsequent development of congestive heart failure. In this 
case, mortality rate is more than 50% [3, 12, 13, 15].
2.2. Mechanisms of cardiotoxicity
Despite almost 60 years of research, the mechanisms to explain DIC are not completely 
understood. It seems to be a multistep process, with different potential pathways involved 
that leads to cardiomyocyte death [11, 16, 17]. Until now, the main mechanisms that have 
been proposed by various research groups include oxidative stress, iron metabolism, Ca2+ 
Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy
http://dx.doi.org/10.5772/intechopen.79588
5
homeostasis dysregulation, sarcomeric structure alterations, gene expression modulation, 
and apoptosis [4, 13, 16, 17].
2.2.1. Oxidative stress
Since the discovery of DOX, oxidative stress is the most frequently proposed mechanism to 
explain the complex pathophysiology of DIC [3, 5, 16]. The myocardium injury evidenced by 
lipid peroxidation occurs as a result of the increase of the reactive oxygen species (ROS) pro-
duction, including superoxide (O
2
−˙) and hydroxyl radicals (OH˙) as well as other non-radicals 




), singlet oxygen (O
2
), etc. [3, 4, 11, 17, 18]. Unlike other 
tissues, the heart is extremely prone to oxidative damage, at least in part, due to lower levels 
of antioxidant enzymes such as peroxidase, catalase, and superoxide dismutase. In addition, 
the chemical structure of DOX contains quinone groups that can be reduced to a semiquinone, 
an unstable metabolite which can react with molecular oxygen (an electron acceptor) and 
rapidly revert to the parent compound. This redox cycle leads to the formation of superoxide 
anion radicals within mitochondria, causing cardiotoxicity [11, 16–20].
The mitochondria have been identified as the main subcellular organelles injured in the heart 
by DIC [4, 17]. DOX is a cationic drug that binds with high affinity to cardiolipin (a phospho-
lipid) forming nearly irreversible complex in the mitochondrial inner membrane [17, 21]. It 
is important to know that cardiolipin is required for the proper functioning of the electron-
transport chain proteins. In this context, evidence suggests that DOX disrupts the cardiolipin-
protein interface, causing more superoxide anion radicals formation [4, 22]. As a result, ROS 
can induce different forms of cardiomyocyte death (apoptosis or necrosis) [17]. Furthermore, 
the reduction of mitochondrial function causes energetic metabolism change evidenced by a 
decrease of the adenosine triphosphate (ATP) production, which may contribute to abnormal 
contraction and relaxation in the failing heart [4, 11, 23].
Other forms of DOX-induced ROS generation in the myocardium include nitric oxide syn-
thases (NOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidases path-
ways. These enzymes interact with DOX and induce oxidative stress [4, 16, 17].
NOS are a group of enzymes responsible for the nitric oxide (NO) production from L-arginine 
and oxygen [24]. The NO generation is altered by the direct binding of DOX to endothelial 
NOS (eNOS) reductase domain, leading to the reduction of the DOX semiquinone radical, 
which reacts with oxygen and produces superoxide. There is evidence to suggest that, in 
low DOX concentrations, eNOS signaling is the main pathway for DOX reduction. In addi-
tion, the increase of DOX-eNOS interaction completely modifies normal functioning of the 
enzyme (NO production) and transforms it into a potent superoxide generator [25]. DOX 
also affects NOS signaling by increasing eNOS transcription and protein activity in bovine 
aortic endothelial cells (BAEC). In this study, BAEC were pretreated with eNOS antisense 
oligonucleotides or antioxidants and the results showed apoptosis decrease [26]. Recently, an 
in vivo study has shown that the pretreatment with folic acid (FA, a modulator of eNOS) pre-
vented DOX-induced increases in superoxide anion and attenuated DOX-induced decreases 
in superoxide dismutase, eNOS phosphorylation, and NO production [27]. Another study 
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showed a decrease in ROS generation, preservation of cardiac function, and reduction of mor-
tality rate after acute and chronic DOX administration in the eNOS knock-out (eNOS−/−) mice 
model, whereas cardiomyocyte-specific eNOS overexpression intensified the pathological 
response to DOX in the heart [28]. In all, these studies demonstrate the importance of eNOS 
signaling in DIC.
Recent evidence suggests that the other isoform called inducible NOS (iNOS) is also involved 
with DOX-induced oxidative stress. In some studies, iNOS transcription and expression are 
increased in mouse and rat hearts and isolated cardiomyocyte after DOX treatment [29–31]. In 
iNOS knock-out (iNOS−/−) mice model, cell death and nitrotyrosine (NT) formation induced 
by DOX were mitigated. The same results were observed when selective iNOS inhibitors 
such as S,S˙-[1,3-phenylene-bis(1,2-ethanediyl)]bis-isothiourea (1,3-PB-ITU) and L-N6-(1-
iminorthyl)-lysine (L-NIL) were administered. In this study, DIC occurs due to the generation 
of peroxynitrite, a potent oxidant which generates secondary free radicals, including nitrogen 
dioxide and carbonate radical [30]. It is possible that the reduction of the peroxynitrite pro-
duction using specific antioxidant(s) is a viable strategy for the decrease of DIC. In support 
of this view, the significant increase of superoxide radical and peroxynitrite induced by DOX 
observed in isolated cardiomyocytes was blunted after treatment with vitamin C (Vit C). 
These results suggest that Vit C provides cardioprotection by reduction of oxidative/nitrosa-
tive stress [31]. Altogether, these works thus also highlight the importance of iNOS signaling 
in DIC.
The activity of the third isoform, neuronal NOS (nNOS), in DOX-induced oxidative stress is 
poorly understood. It appears that the flavin domain is involved with DOX reduction [32]. 
Nevertheless, no changes were observed in nNOS transcription and protein activity after 
the treatment of DOX [30]. Therefore, further studies will be needed to elucidate the role of 
NOS isoforms as well as the therapeutic potential of their pharmacological targeting in DOX-
dependent heart disease.
In relation to NADPH oxidases, also known as NOXs, recent work has identified these 
enzymes as important sources of myocardial ROS [33]. NADPH oxidase is a multicompo-
nent complex that consists of membrane-bound cytochrome b-558, which is a heterodimer of 
gp91phox and p22phox, cytosolic regulatory subunits p47phox and p67phox, and the small 
GTP-binding protein Rac1 [34]. These enzymes mediate the transfer of one electron from 
NADPH to quinone DOX, leading to DOX semiquinone radical. As result, they can produce 
superoxide similar to NOSs. The semiquinone radical also reacts with hydrogen peroxide 
generating hydroxyl radicals [35]. An in vitro study using NADPH oxidase inhibitors (diphe-
nyliodonium and apocynin) on H9c2 cells showed that DOX-induced apoptosis was miti-
gated, demonstrating NADPH oxidase is also involved in the development of cardiac toxicity 
induced by DOX [36]. Furthermore, there is accumulating evidence to support an important 
role for Nox2 NADPH oxidase (one of the seven different NADPH oxidase isoforms) in DIC, 
identified using Nox2-deficient (Nox2−/−) or gp91phox knock-out (gp91−/−) mice [33, 37–39]. 
DOX-induced cardiomyocyte apoptosis and atrophy, interstitial fibrosis, leukocyte infiltra-
tion, and cardiac dysfunction in wild-type (WT) mice were attenuated in Nox2−/− mice [33, 39]. 
DOX-induced superoxide production was also mitigated in this animal model [39].
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Recently, Rac1 has been reported to be a key regulator of oxidative stress due to its ability to 
bind and activate the NADPH oxidases [34]. In this context, a study showed that the dele-
tion of Rac1 (a subunit of the NADPH oxidases complex) in cardiomyocytes impairs DOX-
induced NADPH oxidases activation, ROS generation, DNA fragmentation and apoptosis, 
and improves cardiac function [40]. The same results were observed when NSC23766, a RAC 
inhibitor, was administered. In contrast, the overexpression of Rac1 exacerbated DIC [41]. 
Therefore, Rac is extremely important for the regulation of DIC by NADPH oxidase/ROS-
dependent pathway.
Patient’s genetic susceptibility is another factor that has been considered extremely impor-
tant for the understanding of NADPH oxidases-dependent cardiotoxicity. Single-nucleotide 
polymorphisms (SNPs) in one of the subunits of the NADPH oxidases complex have been 
identified in non-Hodgkin lymphoma patients. After the treatment with DOX, these patients 
developed acute arrhythmias and congestive heart failure. For example, the presence of 
SNP variants in NADPH oxidase subunit NCF4 and in the p22phox and Rac2 subunits were 
linked with the development of chronic and acute DIC, respectively [36]. Thus, detection of 
the genetic polymorphisms in NADPH oxidases complex may help to identify patients who 
have higher risk to develop DIC.
2.2.2. Iron metabolism
It is reported that DOX is able to alter iron metabolism due to its strong affinity for this metal, 
thereby forming iron-DOX complexes which, in turn, react with oxygen and trigger ROS pro-
duction [42]. Thus, the researchers believed that only oxidative stress was responsible for the 
cardiotoxicity induced by iron-DOX complexes. However, in physiological conditions, there 
would not be enough free iron to interact with DOX to the extent necessary to cause cardio-
myopathy [6]. On the other hand, another theory suggests that the effect of DOX on iron 
metabolism occurs due to the interference of this drug in the activity of proteins that transport 
and bind intracellular iron. For example, one of the mechanisms involves the doxorubicinol 
(DOXol), a metabolite of DOX, which removes iron from the catalytic Fe-S cluster of the cyto-
plasmic aconitase (also called iron regulatory protein 1; IRP-1), converting this enzyme to 
a null protein. Consequently, there is an increase in the stability of transferrin mRNA and 
preventing translation of iron sequestration proteins. As a result, reduction of IRP-1 causes an 
increase in free iron, which can lead to free radical production [43, 44]. Furthermore, a recent 
work reports that DOX can also interact with iron-responsive elements (IREs) of the ferritin 
heavy and light chains. It is known that ferritin operates as an iron transporter, reducing free 
iron within the cell. Accordingly, disruption of this protein eventually results in increased free 
iron, which in turn causes myocardium injury [45]. Another work showed iron-overload, mito-
chondrial damage, and mortality after DOX treatment in mice depleted of the iron regulatory 
gene HFE (also known as human hemochromatosis protein). The HFE protein is responsible 
for the regulation of circulating iron uptake [46]. Therefore, free iron accumulation within the 
myocardium after DOX treatment seems to be the major determinant of DIC [20].
It is important to recognize that patients undergoing chemotherapy are submitted blood trans-
fusions and iron supplementation due to abnormal losses and nutritional status deficient, 
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respectively. The fact is that these procedures modify body iron stores. In addition, adult 
and pediatric patients with leukemia can develop a significant level of iron-overload during, 
and as result of, chemotherapy [46]. Thus, it is possible that the reduction of iron levels is an 
effective strategy to prevent DOX-induced cardiomyopathy.
2.2.3. Calcium homeostasis dysregulation
The precise control of calcium levels during the contraction-relation cycle in cardiomyocytes 
is extremely important for normal beat-to-beat contractile activity [47]. Unfortunately, many 
studies suggest that calcium homeostasis dysregulation has a major role in the pathogenesis 
of DIC. To date, severe mechanisms have been proposed that are responsible for an increase 
in calcium intracellular concentrations [4, 16]. One of the mechanisms is related to DOX 
metabolism, which generates a toxic metabolite, DOXol, through a reduction of its carbonyl 
group, capable of inhibiting the sodium-calcium exchanger channel [48]. The sodium/potas-
sium pump of the sarcolemma is also affected by DOXol, which disrupts the sodium gradient 
needed for calcium to flow into the sarcolemma of a cardiomyocyte [49]. Consequently, there 
is an imbalance in the energetics of the myocardium and diminished systolic function [48]. 
Furthermore, it is reported that this secondary metabolite is more difficult to eliminate from 
the cardiomyocyte than the parent drug [50]. Thus, DOXol accumulation contributes signifi-
cantly to the dysregulation of calcium homeostasis, leading to myocardial damage.
Moreover, normal calcium homeostasis is altered by ROS and hydrogen peroxide via dis-
ruption of normal sarcoplasmic reticulum function. This is accomplished by inhibiting the 
Ca2+-ATPase pumps, caused by reducing the expression of SERCA2a mRNA levels and/or the 
direct activation of the ryanodine calcium-release channels themselves [51, 52]. In addition, 
a study suggests that DOX induces calcium release from the sarcoplasmic reticulum due to 
increasing the frequency of opening of these channels [52]. At the same time, DOX induced the 
inhibition of sodium-calcium channels in the plasma membrane as well as increased L-type 
calcium channel activation [53, 54]. DOX has also been shown to decrease the calcium storage 
capacity of mitochondria by specifically activating the selective CsA-sensitive calcium chan-
nel, exacerbating the calcium-overload [49]. As result, an increase of calcium cytoplasmic con-
centrations occurs, leading to mitochondrial dysfunction and apoptosis [55]. Therefore, the 
preservation of calcium homeostasis is essential to prevent DOX-induced cardiomyopathy.
2.2.4. Sarcomeric structure alterations
DIC is also accompanied by disarray and loss of myofilaments of the sarcomere. Titin is a 
giant protein and a key component of the cardiac sarcomeres, extending from the M-line to 
the Z-disk. This protein has multiple functions, from structural to regulatory [56]. Recent 
studies have shown that the loss of integrity or function of titin is directly related to the devel-
opment of dilated cardiomyopathy [57, 58]. It is known that DOX induces rapid degradation 
of titin through the activation of proteolytic pathways, leading to an imbalance in the energet-
ics of the myocardium. Furthermore, studies have shown that the degradation of titin also 
occurs by the activation of calpains (calcium-dependent proteases) and reported that the inhi-
bition of this protein is responsible for preserving cardiac function after DOX treatment [59]. 
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Another study showed that the depletion of the cardiac ankyrin repeat protein (CARP), which 
are important in negative regulation of cardiac genes expression, leads to marked sarcomeric 
disarray [60]. Taken together, these studies thus also highlight the importance of sarcomeric 
structure stability to prevent DIC. It is necessary to recognize that other proteins are essential 
for sarcomeric cytoskeleton such as α-actinin, myomesin, and nebulin, and further studies 
should be performed to verify the DOX effect on these proteins.
2.2.5. Gene expression modulation
Some studies suggest that DOX down-regulates cardiac muscle-specific proteins such as 
contractile proteins, mitochondrial proteins, sarcoplasmic reticulum proteins, and others. 
Suppression of the cardiac muscle gene is associated with abnormal contraction and relax-
ation observed after DOX treatment [3, 11]. Another study showed that DOX induces deple-
tion of GATA-4, leading commitment of the regulation of sarcomeric proteins expression such 
as myosin heavy chain and troponin I [61, 62]. In addition, suppression of GATA-4 induced by 
DOX is also related to the induction of apoptosis, suggesting the essential role of GATA-4 in 
cell survival [63, 64]. Regarding mitochondrial proteins, there is evidence that the suppression 
of these proteins after DOX treatment results in disruption of myocardial energy production, 
thereby causing cardiac dysfunction [3].
On the other hand, DOX induces upregulation of endothelin-1 (ET-1) and its receptors’ expres-
sion [65, 66]. An in vivo study has shown that DOX-induced cardiotoxicity was reduced when 
mice were pretreated with the combined endothelin A/B antagonist (bosentan). In addition, 
the authors suggest that the reduction of TNF-α and BAX expression, lipid peroxidation, and 
increased expression of GATA-4 are responsible for cardioprotective effects observed in this 
study [67]. However, it is unclear if combined blocking of endothelin A/B receptors is neces-
sary or whether selective inhibition of one of the ET-1 receptors is sufficient for the observed 
cardioprotection. In this context, a recent study evaluated the effects of dual (bosentan) and 
single endothelin receptor antagonism through sitaxentan (receptor A blocker) or BQ788 
(receptor B blocker). The results demonstrated more beneficial effects of cardiac function 
when both receptors were blocked [66]. Taken together, these data support a substantial role 
of endothelin-1 signaling as a mediator of DIC.
2.2.6. Apoptosis
DOX can induce apoptosis through different mechanisms, which have been extensively 
studied in both acute and chronic cardiotoxicity. As mentioned in this chapter, one path-
way involves ROS production and oxidative mechanisms and it is accepted that both the 
extrinsic and intrinsic apoptotic pathways are involved [17]. Increased oxidative stress has 
been shown to promote apoptosis and antioxidants have been shown to inhibit this process 
[7]. Oxidative stress also is known to activate apoptosis-signal regulating kinase-1 (ASK1), 
which activates the c-Jun NH2-terminal kinase (JNK) and p38 MAPK pathways to induce 
apoptosis [68]. In addition, it is reported that transcription factor NF-κB activated by ROS 
in DOX-treated neonatal rat cardiomyocytes and myocardium exerts a proapoptotic effect 
via direct activation of apoptotic genes, including FasL, Fas, c-Myc, and p53 [69–71]. The 
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activation of p53 by superoxide and hydrogen peroxide activates Bax genes, causing apopto-
sis [72, 73]. At the same time, evidence indicates that there is also an increase in the production 
of proapoptotic proteins as a result of p53 stabilization through increased heat shock protein 
(Hsp)25 production due to the activation of heat shock factor 1 (HSF-1), which is induced by 
DOX-dependent oxidative stress. In contrast, several studies suggest that Hsp proteins, such 
as Hsp27, Hsp10, Hsp20, and Hsp60, are involved in the prevention of DOX-induced apop-
tosis and myocardial dysfunction [74, 75]. Overexpression of Hsp27 plays a beneficial role in 
the regulation of oxidative stress responses and maintenance of mitochondrial function [74]. 
Regarding Hsp10 and Hsp60, overexpression of these proteins is associated with an increase 
in the post-translational modification of Bcl-2 proteins, which are important for the activa-
tion of anti-apoptotic pathways [75]. In addition, it is reported that overexpression of Hsp20 
inhibits DOX-triggered cardiac injury, and these beneficial effects appear to be dependent 
on protein kinase B (also known as Akt) activation [76]. Therefore, more studies should be 
performed to understand the anti- and/or proapoptotic signaling pathways activated by Hsp 
proteins and their relationship to DOX.
Recently, an in vitro study using cardiomyocytes derived from human induced pluripotent 
stem cells (CM-iPSC) showed that DOX significantly upregulated the expression of death 
receptors (DRs) (TNFR1, Fas, DR4, and DR5) at both protein and mRNA levels. This study 
also showed that spontaneous apoptosis is exacerbated by death ligands including TNF-
related apoptosis inducing ligand (TRAIL) [77]. Another study reported that Toll-like recep-
tor-2 (TLR-2) functions as a novel “death receptor” that employs the apoptotic apparatus 
such as FADD and caspase 8 without a conventional cytoplasmic death domain. In this 
study, the authors observed reduction of apoptosis in myocardium after DOX treatment 
in TLR-2-knock-out mice (TLR-2−/−) when compared to wild-type mice [78]. These results 
demonstrate that the induction of death receptors in cardiomyocytes is probably another 
mechanism by which DOX causes cardiotoxicity.
DOX is also appearing to influence caspase activity. Using both rat primary cultured car-
diomyocytes and rat hearts from an animal model, the study demonstrated that DOX treat-
ment induces apoptosis through the activation of caspase-3 activity [79]. In addition, another 
study showed that caspase-3 can be activated after Akt and Bad phosphorylation caused 
by DOX-induced upregulation of Ser/Thr PP1 phosphatase [76]. In support of this view, in 
TLR-2-knock-out mice, DOX-induced caspase-3 activity was decreased and this effect is a 
result of inhibition of NF-κB activation and reduction of proinflammatory cytokine [78, 80]. 
In all, these data demonstrated the need to understand the molecular signaling pathways that 
mediate DOX-induced cardiomyocyte apoptosis. This knowledge is extremely important for 
the advancement and development of new approaches for the treatment and/or prevention 
of DIC.
2.2.7. Other emerging mechanisms: role of microRNAs
Several studies indicate DIC is associated with modulation of microRNAs due to their role 
in all cardiac functions, including conductance of electrical signals, heart muscle contrac-
tion, and growth [81]. It is reported that a group of microRNAs, such as miR-34a, miR-34c, 
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miR-208b, miR-215, miR-216b, and miR-367 are upregulated in the rat heart when increasing 
doses of DOX are administered. In this same condition, there is evidence that miR-21, miR-
34a, miR-208a, miR-208b, miR-221, miR-222, and miR-320a are upregulated in mice myocar-
dium [81, 82]. On the other hand, other microRNAs including Let-7 g, miR-30a, miR-30c, and 
miR-30e are downregulated in rat myocardium after DOX treatment, confirming the role of 
DOX in the modulation of microRNAs [81].
Recently, the effects of DOX on the expression of miR-21 were examined in rat H9C9 cardio-
myocytes. This study showed that overexpression of miR-21 attenuated DOX-induced apop-
tosis, whereas knocking down its expression increased DOX-induced apoptosis. In addition, 
the authors suggest that miR-21 protects cardiomyocytes by modulating the anti-proliferative 
factor, B cell translocation gene 2 (BTG2) [83]. Furthermore, the effects of DOX on expression 
of miR-208a were investigated in Balb/C mice hearts. In this study, DOX significantly upregu-
lated miR-208a, downregulated GATA4, and increased myocyte apoptosis. In contrast, thera-
peutic silencing of miR-208a recovered GATA4 and BCL-2 and decreased apoptosis [84]. DOX 
also induced overexpression of miR-146a, which are responsible for downregulating ErB2 
receptor tyrosine kinase 4 (ErB4), a key component of neuregulin-1-ErbB signaling, resulting 
in apoptosis in cardiomyocytes [85].
In turn, a recent study demonstrated that the miR-30 family, which is downregulated by 
DOX, is involved in the modulating of β-adrenergic and mitochondrial apoptotic pathways. 
In this study, the authors identify GATA-6 as a mediator of DOX-associated reductions in 
miR-30 expression. Moreover, they showed that overexpression of miR-30 protects cardio-
myocytes from DOX-induced apoptosis [86]. Therefore, these data highlight the importance 
of modulating microRNA expression as well as providing a novel therapeutic approach to 
DIC prevention.
2.3. Strategies for heart protection
Since several mechanisms are involved in the development of cardiac toxicity, different strate-
gies are being performed to prevent DOX-induced cardiomyopathy. One of these strategies is 
the use of dexrazoxane (also known as ICRF-187), an adjunctive agent derivative of ethylene-
diaminetetraacetic acid (EDTA), which acts as a free radical scavenger. In this case, dexrazox-
ane is an EDTA-like chelator that interferes with iron-mediated oxygen free radical generation 
and, consequently, lipid peroxidation [87, 88]. The beneficial effects of dexrazoxane have been 
demonstrated in murine [89, 90] and canine [91, 92] models. Further, a meta-analysis of six 
randomized trials that included 1013 adult and pediatric patients demonstrated significantly 
reduced incidence of heart failure after dexrazoxane treatment, confirming its beneficial 
effects [93]. In addition, cardioprotective effects have been observed in children with high-risk 
acute lymphoblastic leukemia (ALL) receiving chronic DOX (10 doses of 30 mg/m2) [94, 95]. 
The studies concluded that treatment with dexrazoxane is justified individually when the risk 
of cardiac dysfunction is expectedly high [87]. Unfortunately, according to the current Food 
Drug Administration (FDA) approval statement and European Medicines Agency (EMA), the 
use of this drug as a cardioprotective is limited to women with metastatic breast cancer who 
have received cumulative doses of 300 mg/m2 DOX [95, 96].
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Another strategy that has been evaluated is the use of angiotensin-converting enzyme (ACE) 
inhibitors, including enalapril, zofenopril, and lisinopril. ACE inhibitors are commonly used 
in patients with heart failure as afterload-reducing agents. In addition to their features as 
an effective ACE inhibitor, these drugs act as antioxidant and, thus, may contribute to pre-
vent cardiac toxicity [97]. In support of this view, recent preclinical study demonstrated that 
administration of enalapril attenuated DOX-induced cardiac dysfunction via preservation of 
mitochondrial respiratory efficiency and reduction in DOX-associated free radical generation 
[98]. Unluckily, in long-term survivors of childhood cancer treated with DOX, the beneficial 
effect of enalapril-induced improvement in left ventricle structure and function was lost after 
6 or 10 years. It is important to mention that ACE inhibitors have adverse side effects and, 
therefore, the choice of this drug as a cardioprotective agent during cancer treatment should 
be carefully evaluated [99].
Another antioxidant that has already been tested against DOX-induced cardiomyopathy is 
vitamin E. A study has shown that vitamin E only prevents the acute effects of DOX car-
diotoxicity in mice [100]. Several other antioxidants also have been tested with limited suc-
cess, including vitamin C, reduced glutathione, selenorganic compound PZ51, oleanolic and 
ursolic acids, and ambroxol [101–105]. On the other hand, probucol, a lipid-lowering agent 
and potent antioxidant, provided complete protection against DOX-induced cardiomyopathy 
and heart failure in animal experiments without interfering with the antitumor properties of 
this antibiotic [106, 107]. In this case, it is extremely important that clinical trials using DOX 
therapy in combination with probucol are performed to determine a new preventive cardio-
toxicity strategy. This approach was recently tested using a β-adrenergic receptor blocker and 
also an antioxidant agent called carvedilol. As result, this drug protected systolic functions 
of the left ventricle due to reducing DIC [108]. Therefore, the use of carvedilol may become a 
promising strategy to improve DIC. However, more studies are needed to assess whether the 
beneficial effect observed on cardiac function is preserved over the years.
In addition to the antioxidant agents, accumulating evidence indicates that cardiac α1-adrenergic 
receptors (α1-ARs) protect cardiomyocytes from DIC. In particular, the stimulation of α1-AR-
specific agonists phenylephrine (PE) and dabuzalgron have been shown to reduce apopto-
sis, interstitial fibrosis, and myocardial dysfunction caused by DOX. This protective effect is 
associated, at least in part, with the expression of anti-apoptotic proteins of the Bcl2 family 
and preservation of mitochondrial function [64, 109]. Thus, further studies will be needed to 
elucidate the full mechanisms responsible for the cardioprotective effects observed up to now.
2.4. Breakthroughs and challenges in basic and clinical research
Although therapeutic strategies to prevent cardiomyopathy have been proposed for more 
than four decades, it is important to highlight that there is still no specific treatment for total 
recovery of the myocardial injury caused by DOX. In this case, cardiac transplantation remains 
a vital option for patients with end-stage heart failure due to DOX-induced cardiomyopathy 
[3]. However, the major problem is the long time of wait in the queue of transplant due to low 
donor/acceptor ratio. Statistical data show that 10–20% of the patients in the waiting queue 
come to death annually [110].
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In this scenario, in which therapeutic options for DOX-induced cardiomyopathy are insufficient, 
a newly emerging strategy is cell therapy. The principle of cell therapy is to restore the function of 
an organ or tissue by transplanting new cells [111]. In this context, a study has shown that trans-
planted mouse embryonic stem cell (ESC) in DOX-induced cardiomyopathy mice model attenu-
ated various pathological mechanisms such as: (1) cardiomyocyte apoptosis due to inhibition 
of phosphoinositol-3-kinase (PI3K)/Akt and ERK pathway; (2) cardiac fibrosis; (3) cytoplasmic 
vacuolization; and (4) myofibrillar loss [112]. Although beneficial effects have been observed in 
this study, the teratogenic potential of these cells represents serious limitation to their use [113, 
114]. In fact, experimental models of myocardial infarction have demonstrated the formation of 
teratomas after the transplantation of undifferentiated ESC [115, 116]. Thus, to overcome this limi-
tation, several studies suggest the use of already differentiated ESC in cardiomyocytes [116, 117].
Considering that DOX causes cardiomyocyte death through the activation of different molec-
ular and pathophysiological mechanisms, this therapeutic approach seems to be promissory 
for future application against DIC. In support of this view, recently, our research group has 
shown that the transplant of cardiomyocytes derived from mouse ESC (CM-mESC) improved 
cardiac function and electrical activity of the mice hearts with DIC, as well as reduced the 
percentage of cardiomyocyte apoptosis [118].
For clinical research, cardiomyocytes derived from human induced pluripotent stem cells 
(CM-iPSC) are potential cell sources for cardiomyocyte transplantation therapy. The genera-
tion of induced pluripotent stem cells (iPSC) from human somatic cells through overexpres-
sion of four transcription factors (OCT4, SOX2, c-Myc, and KLF4) represented a scientific 
milestone opening new perspectives for treatment of heart diseases. In addition to showing 
the same characteristics of ECS and, thus, the ability to differentiate into cardiomyocytes, 
these cells are not associated with immune rejection [119, 120].
Currently, the great challenge for the scientific community is the development of pro-matu-
ration strategies to obtain human adult cardiomyocytes in vitro, with ventricular-like pheno-
type based on action potential, genetic, morphological, and metabolic characteristics [121]. 
Once maturation is achieved, CM-iPSC are a viable option as an autologous cell source for 
cardiac repair and a powerful tool for treatment of cardiovascular diseases, including DIC.
3. Conclusion
DIC is an important public health concern given the fact that this disease may not to be detected 
for many years and remains a life-long threat. Mechanisms contributing to the development of 
cardiomyopathy involve (1) free radical generation; (2) alteration in iron metabolism through 
iron-DOX complex formation or interference in the proteins’ activity that transport and bind 
intracellular iron; (3) increased calcium intracellular concentrations; (4) disarray and loss of 
myofilaments of the sarcomere; (5) gene expression modulation; (6) activation of apoptosis 
by different signaling pathways; and (7) modulating microRNA expression. Based on these 
mechanisms, a variety of strategies to prevent cardiotoxicity have been tried, including the use 
of iron-chelating antioxidants and adrenergic receptor agonists. However, so far, the ability of 
these treatments to protect the heart from DOX-induced damage has been limited. Since DOX 
causes cardiomyocyte death, one recent approach that has shown promise is the transplant of 
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CM-iPSC. In this context, the scientific community has been engaged in the establishment of 
pro-maturation protocols to obtain adult human cardiomyocytes in vitro. Once this challenge 
has been overcome, we believe that cell therapy with CM-iPSC may be a promising strategy 
for the development of effective therapy against DIC.
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